The U.S. Food and Drug Administration has granted approval to Eli Lilly’s Zepbound (tirzepatide) injection, making it the only obesity treatment that activates both GIP and GLP-1 hormone receptors. This medication is tailored for adults with obesity or overweight conditions associated with weight-related medical issues such as hypertension and type 2 diabetes. Zepbound is recommended alongside a reduced-calorie diet and increased physical activity.

Groundbreaking Clinical Trial Results Set the Stage for Zepbound

Zepbound’s approval comes on the heels of impressive phase 3 clinical trial results. In the SURMOUNT-1 study involving adults with obesity, participants experienced significant weight loss over a 72-week period when using Zepbound as part of a comprehensive diet and exercise plan. On average, individuals lost 34 to 48 pounds depending on the dosage, a substantial increase compared to the placebo group.

Patient-Centric Approach to Obesity and Weight Management

The Obesity Action Coalition has voiced strong support for new treatments like Zepbound, highlighting the need for innovative solutions in managing obesity. As obesity can lead to severe health issues, Zepbound’s introduction is seen as a beacon of hope for effective weight management strategies.

Zepbound’s Accessibility and Pricing Details

Eli Lilly has announced Zepbound’s expected availability in the U.S. market by year-end with a competitive pricing strategy. The list price of Zepbound is set lower than its contemporaries, aiming to enhance patient access. Moreover, Eli Lilly is preparing a commercial savings card program to facilitate affordability for those benefiting from Zepbound, with potential costs as low as $25 for eligible commercially insured patients.

  Eli Lilly and Company, Lilly, obesity, Tirzepatide, Type 2 Diabetes, US FDA, USA, weight loss, Zepbound